This last evidence, together with the correlation between E2F3 expression and the poor outcome in NB patients despite RB1 levels, lets us hypothesize that a high dosage of MYCN in the cell may overcome RB function to promote an E2F-driven transcriptional activation. This evidence concerns the gene RB1 and neuroblastoma.